Folate-Functionalized Mesoporous Silica Nanoparticles as a Liver Tumor-Targeted Drug Delivery System to Improve the Antitumor Effect of Paclitaxel

Figure 4

(a) The DSC patterns. (b) PXRD patterns of (A) pure PTX, (B) PPM, (C) PPFA, (D) MSNs-PTX, (E) FA-PEG-MSNs-PTX, (F) MSNs, and (G) FA-PEG-MSNs. (c) Immunoblots showing the effect of FA-PEG-MSNs-PTX on the expression of Bcl-2, caspase-3, Bax in cells treated with (A) the control group, (B) pure PTX, (C) FA-PEG-MSNs-PTX, and (D) MSNs-PTX. (d) The flow cytometry plots of SMMC-7721 cells treated with (A) the control group, (B) pure PTX, (C) FA-PEG-MSNs-PTX, and (D) MSNs-PTX.

(a)

(b)

(c)

(d)